Primary pulmonary hypertension

Thorax

Volumn 54, Issue 12, 1999, Pages 1107-1118

  Peacock, A J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOREX; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; COCAINE; ESTROGEN; FENFLURAMINE; METHAMPHETAMINE; ORAL CONTRACEPTIVE AGENT; TRYPTOPHAN;

DISEASE CLASSIFICATION; HUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SCREENING; SURVIVAL;

EID: 0032700801     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.12.1107     Document Type: Review

References (91)

1. Rich S, ed. Primary pulmonary hypertension. Executive summary from the World Symposium. Primary Pulmonary Hypertension. World Health Organisation, 1998.
2. Langleben D. Familial primary pulmonary hypertension. Chest 1994;105:13-68.
3. Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139-48.
4. Gertner HP. Pulmonary hypertension 'plexogenic pulmonary arteriopathy' and the appetite suppressant drug aminorex: Post or proctor? Bull Eur Physiopathol Respir 1979;15:897-923.
5. Abenheim I., Moride Y, Breno F, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
6. Wagner PD. Impairment of gas exchange in liver cirrhosis. Ear Respir J 1995;8:1993-5.
7. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: Analysis of its pathophysiology and clinical laboratory and haemodynamic manifestations. J Am Coll Cardiol 1991;17:492-8.
8. Hadengue A, Benyahoun MK, Lebrec D, et al. Pulmonary hypertension-complicated portal hypertension: Prevalence in relation to haemodynamics. Gastroenterology 1991;100: 520-8.
9. Herve P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-66.
10. Mitchell DM. New developments in the pulmonary discuses affecting HIV infected individuals Thorax 1995;50:294-302.
11. Petitpret ZP, Brenot F, Azarian R. Pulmonary hypertension patients with human immunodeficiency virus infection: Comparison with primary pulmonary hypertension. Circulation 1994;89:2722-7.
12. Badesch DB, Wynne KM, Bonvallet S, et al. Hypothyroidism and primary pulmonary hypertension: An autoimmune pathogenetic link? Ann Intern Med 1993;119:444-6.
13. Ohashi M, Sato K, Suzuki S. Doppler echocardiographic evaluation of latent pulmonary hypertension by passive leg raising. Coronary Artery Dis 1997;8:651-5.
14. Von Euler US, Liljestrand J. Observations on the pulmonary artery blood pressure in the cat. Acta Physiol Scand 1946;12:301-20.
15. Wagenwoort CA. Primary pulmonary hypertension: Pathology. In: Peacock AJ, ed. Pulmonary Circulation Handbook for Clinicians. London: Chapman and Hall, 1996:325-38.
16. Berghuber OC. Echocardiographic measurements of the pulmonary circulation and right heart. In: Peacock AJ, ed. Pulmonary Circulation Handbook for Clinicians. London: Chapman and Hall, 1996:41-9.
17. Eysmann SB, Palevsky HI, Reichek N, et al. Two dimensional and doppler echocardiography and cardiac catheterisation correlates of survival in primary pulmonary hypertension. Circulation 1989;80:353-60.
18. Tei C, Dujardin KS, Hodge DO. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 1996;9:838-47.
19. Torbicki IA, Hawrylkiewicz I, Zielinski J. Value of M-Mode echocardiography in assessing pulmonary artery pressure in chronic lung disease. Bull Eur Pathophysiol Respir 1987;23:233-9.
20. Barst TRJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostanol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
21. D'Alonzo GE, Gianotti L, Dantzker DR. Non-invasive assessment of haemodynamic improvement during chronic vasodilator therapy in obliterative pulmonary hypertension. Am Rev Respir Dis 1986;133:380-4.
22. Raeside DA, Smith A, Clelland J, et al. Exercise testing during continuous pulmonary artery pressure monitoring: Can variables be identified which may predicted responses in the pulmonary circulation? Am J Resp Crit Care 1997; 155:A629.
23. Tardivon AA, Mousseaux E, Brenot F, et al. Quantification of haemodynamics in primary pulmonary hypertension with magnetic resonance imaging? Am J Respir Crit Care Med 1994;150:1075-80.
24. Sitbon O, Umbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265-70.
25. Morgan JM, McCormack DG, Griffiths MJD, et al. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 1991;84:1145-9.
26. Baer S, Schrader BJ, Kaufman E. Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. J Am Coll Cardiol 1993;21:413-8.
27. Rich S, Kaufman E. High dose titration of calcium channel blockers for primary pulmonary hypertension: Guidelines for short-term drug testing. J Am Coll Cardiol 1991;18: 1323-8.
28. Rubin L, Groves B, Reeve J, et al. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982;66:334-8.
29. Jolliet P, Bulpa P, Thorens J, et al. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: Predictive ability and consequences on haemodynamics and gas exchange. Thorax 1997;52:369-72.
30. Nootens M, Schrader B, Kaufmann E, et al. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995;107:54-7.
31. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension: Experience from the National Institutes of Health Registry on primary pulmonary hypertension. Am Rev Respir Dis 1989;140:1623-30.
32. Raeside DA, Chalmers G, Clelland J, et al. Pulmonary artery pressure variation in patients with connective tissue disease: 24 Hour ambulatory pulmonary artery pressure monitoring. Thorax 1998;53:857-62.
33. Koniars L, Cutaia M. Initial steps towards consensus in the management of primary pulmonary hypertension. Chest 1098;114:34 5.
34. Peacock AJ, Vasodilators in pulmonary hypertension. Thorax 1993;48:1196-9.
35. Rich S, Kaufman E, Levy PDS. The effects of high dose calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
36. Fuster V, Steel PM, Edwards WD, et al. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1994;70:580-7.
37. Rich S, Hart K, Kieras K, et al. Thromboxane synthetase inhibition in primary pulmonary hypertension. Chest 1987; 91:356-16.
38. Rich S, Brundidge BH. High dose calcium channel blocking therapy for primary pulmonary hypertension. Evidence of long-term reduction in pulmonary artery pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-41.
39. Raeside D, Smith A, Brown A, et al. Effects of diltiazem on exercise tolerance in patients with pulmonary hypertension secondary to connective tissue disease. Am J Respir Crit Care Med 1998;157:A595.
40. Honey M, Cotter I, Davies N, et al. Clinical and haemodynamic effects of diazoxide in primary pulmonary hypertension. Thorax 1980;35:269-76.
41. Ikram H, Maslowski AH, Nicholls GM, et al. Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension. Br Heart J 1982;48:541-5.
42. Leier CV, Bambach D, Nelson S, et al. Captopril and primary pulmonary hypertension. Circulation 1983;67: 155-61.
43. Packer M, Greenberg B, Massie B-H. Deleterious effects of hydralazine in patients with pulmonary hypertension. N Engl J Med 1982;306:1326-31.
44. Rich S, Seidlitz M, Dodin E, et al. Short-term effects of digoxin. Patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-92.
45. Ribas J, Angrill J, Barbera J, et al. Isosorbide 5 mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. Eur Respir J 1999 (in press).
46. Rubin LJ, Groves BM, Reeves JT. Prostacyclin induces acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982;66:334-8.
47. Higenbottam T, Wheeldon D, Wells F, et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol. Lancet 1984:46-7.
48. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): Results of a randomised trial. Ann Intern Med 1990;112:185-91.
49. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
50. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolised prostacyclin and iloprost in severe pulmonary hypertension. Ann. Intern Med 1996;124:20-4.
51. Mikhail G, Gibbs SR, Richardson M, et al. An evaluation of nebulised prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart. J 1997;18: 1499-501.
52. Walmrath D, Schermuly R. Pilch J, et al. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J 1997;10:1084-92.
53. Higgenbottam TW, Butt AY, Dinh-Xuan SL. Treatment of pulmonary hypertension with a continuous infusion of prostacyclin analogue Iloprost. Heart 1998;79:175-9.
54. Miyata M, Ueno Y, Sekine H, et al. Protective effects of beraprost sodium, a stable prostacyclin analogue in the development of monocrotaline-induced pulmonary hypertension. J Cardiovascular Pharm 1996;27:20-6.
55. Saji T, Osawa Y, Ishikita T, et al. Short-term haemodynamic effects of a new oral PGI, analogue beraprost in primary and secondary hypertension. Am J Cardiol 1996;78:244-7.
56. Rich S, Lamb W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. Am J Cardiol 1983;51:1560-1.
57. Kerstein D, Levy PS, Hesu DT, et al. Balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995;91:2028-35.
58. Rich S, Dudin E, McLaughlin VV. Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J Cardiol 1997;80:369-71.
59. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-7.
60. D'Alonzo GE, Barst RJ, Ayrs SM, et al. Survival in patients with primary pulmonary hypertension. Results from national prospective registry. Ann Intern Med 1991;115: 343-9.
61. Nootens M, Friels S, Kaufman E. Timing of single lung transplantation for primary pulmonary hypertension. J Heart Lung Transplant 1994;13:276-81.
62. Speich R, Jennir Opravil M, et al. Primary pulmonary hypertension and HIV infection. Chest 1991;100:1268-71.
63. Mett SA, Palevsky HI, Pietra G, et al. Primary pulmonary hypertension associated with human immunodeficiency virus infection. Am Rev Respir Dis 1992;145:1196-200.
64. Polos PG, Wolfe D, Harley RA. Pulmonary hypertension and human immunodeficiency virus infections. Chest 1992; 101:474-8.
65. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
66. Archer SL, Djaballah K, Humbert M, et al. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 1998; 158:1061-7.
67. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-2.
68. Curfman GD. Diet pills redux. N Engl Med 1997;337:629-30.
69. Delcroix M, Kurz X, Walckiers D, et al. High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. Eur Respir J 1998;12:271-6.
70. Herve P, Lebrec D, Breno TF, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11: 1153-66.
71. Horn CA, Pulmonary hypertension in autoimmune disease. Chest 1993;104:279-82.
72. Vergnon JM, Barthelemy JC, Riffat J. Raynaud's phenomenon of the lung. Chest 1992;101:1312-7.
73. Morgan JM, Griffiths M, Dubois RM. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest 1991;99:551-6.
74. Morelli S, Giordano M, DeMarzio PD, et al. Pulmonary arterial hypertension responses to immunosuppressive therapy in system lupus erythematosis. Lupus 1993;2: 367-9.
75. Scott PH, Peacock AJ. Cell signalling in pulmonary vascular cells: Do not shoot the messenger. Thorax J 1996;51:61-6.
76. Lloyd JE, Primm RK, Newman JH. Family primary pulmonary hypertension: Clinical patterns. Am Rev Respir Dis 1984;129:194-7.
77. Lloyd JE, Newman JH, Lane J, et al. Progress in a gene search for familial primary pulmonary hypertension by an international consortium. Am J Respir Crit Care Med 1998; 157:A593.
78. Morse JH, Jones AC, Barst RJ, et al. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q 31-32. Circulation 1997;95:2603-6.
79. Archer SL, Djaballah K, Humbert M, et al. Nitric oxide deficiency in fenfluramine and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 1998; 158:1061-7.
80. Brett SJ, Gibbs JSR, Pepper J, et al. Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension. Thorax 1996; 51:89-91.
81. Cailes J, Winter S, Dubois R. Defective endothelial-mediated pulmonary vasodilation in systemic sclerosis. Chest 1998;114:78-84.
82. Kharitonov SA, Cailes JB, Black CM, et al. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997;52:1051-5.
83. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide sythase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21.
84. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin 1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
85. Egermayer R, Town GI, Peacock AJ. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 1999;54;161-8.
86. Christman BW, McPherson CD, Newman JH, et al. An imbalance between excretion of thromboxane and prostacyclin metabolised in pulmonary hypertension. N Engl J Med 1992;327:70-5.
87. Yuan XJ, Wang J, Juhaszova M, et al. Attenuated K′ (potassium) channel gene transcription in primary pulmonary hypertension. Lancet 1998;352:726-7.
88. Herve P, Launay JM, Scrobohaci MN, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249-54.
89. Bishop JF, Butt RP, Low RB. The effect of mechanical forces on cell function: Implications for pulmonary vascular remodelling due to hypertension. In: Bishop JF, Reeves JT, Laurent GJ, eds. Pulmonary Vascular Remodelling. Portland Press Research Monographs, 1995.
90. Welsh DJ, Scott P, Plevin R, et al. Hypoxia enhances cellular proliferation and inositol 145 triphosphate generation in fibroblast from bovine pulmonary artery but not from mesenteric artery. Am J Respir Crit Care Med 1998;158: 1750-62.
91. Brij SO, Peacock AJ. Cellular responses to hypoxia in the pulmonary circulation. Thorax 1998;53:1075-9.